Inclusion Criteria:

          -  Age ≥ 18 years

          -  Willing and able to give written informed consent

          -  Have histologically or cytologically confirmed advanced or metastatic solid tumor

          -  There is no available standard systemic therapy available for the patient's tumor
             histology and/or molecular biomarker profile; or standard therapy is intolerable, not
             effective, or not accessible; or patient has refused standard therapy

          -  Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

          -  Adequate cardiovascular, hematological, liver, and renal function

          -  Willing to comply with all protocol-required visits, assessments, and procedures

        Exclusion Criteria:

          -  Is currently receiving another study therapy or has participated in a study of an
             investigational agent and received study therapy within 4 weeks of Cycle 1, Day 1

          -  Received prior palliative radiation within 7 days of Cycle 1, Day 1

          -  Have primary central nervous system (CNS) disease or known active CNS metastases
             and/or carcinomatous meningitis

          -  Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal
             dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may
             affect drug absorption

          -  Active, clinically significant interstitial lung disease or pneumonitis

          -  History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose
             of study treatment

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO

          -  Have any underlying medical condition, psychiatric condition, or social situation
             that, in the opinion of the Investigator, would compromise study administration as per
             protocol or compromise the assessment of AEs

          -  Are pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the trial